Beijing Darwin Cell Biotechnology Co.

Beijing Darwin Cell Biotechnology Co., Ltd. was founded in 2016, is a national high-tech enterprise, Beijing specializing in small and medium-sized enterprises.Founded on June 27, 2016, Beijing Darwin Cell Biotechnology Co., Ltd. is a national high-tech enterprise focusing on biotechnology research and development, and a Beijing Specialized Specialized Specialized Specialized Specialized Specialized Specialized Specialized Specialized Specialized Specialized Specialized Specialized Specialized Small and Medium-sized Enterprise. The company is the lead unit of the first batch of Science and Innovation Collaborative Consortium in Beijing, and is the only unit in the field of biomedical innovation. The Beijing Neural Repair Industry Innovation Center led by the company has completed pre-approval, and the company is currently applying for the Beijing Future Industry Research Base.

Beijing Darwin Cell Biotechnology Co., Ltd. is a high-tech enterprise focusing on the research and development of innovative biotechnology, covering three generations of cellular biotechnology: stem cells, exosomes, and protein polymers; relying on the world's leading mesenchymal stem cell stress-induced protein polymer extraction technology (ECIWEP) with its own intellectual property rights, the company focuses on the research and development of innovative biopharmaceuticals and biomaterials in the fields of central nervous system, articular and cartilage repair and organ repair. We specialize in the research and development of innovative biopharmaceuticals and biomaterials in the fields of central nervous system, articular cartilage repair, organ repair and so on. The indications are stroke, acromegaly, Alzheimer's and other neurodegenerative diseases.

Our headquarter covers an area of 6,500 square meters, with three R&D centers, two pilot platforms and one clinical center; 33 R&D elites, 23 senior researchers and 50 clinical research experts. At present, the company has four major technology platforms: stem cell stress induction technology platform, functional protein discovery and screening technology platform, neurological disease drug efficacy screening platform and IIT clinical trial platform. There are 3 core drug pipelines and 7 reserve pipelines; among them, 90% is an innovative biopharmaceutical, 80% is targeted at the treatment of neurological diseases, and 50% meets the criteria for breakthrough therapies.

Alitol, the first biologic Class 1 new drug product, showed breakthrough efficacy and good safety. 2023, we launched the "necklace technology" research project at Beijing Tiantan Hospital, the National Center for Neurology, and two "IIT" double-blind clinical trials for rare diseases such as acromegaly and stroke; the innovative biomaterial launched clinical trials in August 2024; and the innovative biomaterial launched clinical trials in August 2024. In 2023, we launched the research project of "necklace technology" at Beijing Tiantan Hospital, the National Neurological Medical Center, and initiated two double-blind clinical trials of IIT for rare diseases such as acromegaly and stroke; in August 2024, we initiated the clinical trials of innovative biomaterials.

Corporate Mission

Making life more quality

Corporate Vision

Dedicated to developing and exploring groundbreaking, innovative therapies that fulfill our commitment to patients, employees and society.

Enterprise achievements and honors

National High-tech Enterprise

Joint State Laboratory

Beijing "Specialized, Specialized and New" Small and Medium-sized Enterprises

Beijing "Innovative" Small and Medium-sized Enterprises (SMEs)

2023 Belt and Road Health Industry High Quality Development Leaders

Leader of Beijing Municipal Association for Science and Technology's Science and Innovation Consortium

Beijing Neural Repair Industry Innovation Center Lead Unit

Beijing Intellectual Property Pilot Unit

Intellectual Property Management System Certification

Certificate of Intellectual Property Gradient Incubation

New Quality Productivity Enterprises

Lead operating agency

Beijing Neural Repair Industry Synergy Consortium

Galen Institute of Neuroscience